OncoPrism-HNSCC is a laboratory developed test that predicts disease control rate and progression free survival in response to anti-PD-1 therapy in pre-treatment RM-HNSCC patients. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.